The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305621 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2024. Verfasst von Bingjia Qu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Bayes Theorem, Pyrimidines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Program of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This study aims to evaluate the efficacy and safety of JAK inhibitors in the treatment of patients with RA.
Methods
The databases CNKI, VIP, Wanfang, CBM, and PubMed, Embase, Cochrane Library and Web of Science were searched to identify relevant randomized controlled trials (RCTs), all from the time of database creation to April 2024. Screening, data extraction, and risk of bias assessment (using Review Manager-5.3 software) were independently performed by at least two authors. The network meta-analysis was conducted using R 4.1.3 software. PROSPERO registration number: CRD42022370444.
Results
Thirty-three RCTs included 15,961 patients The experimental groups involved six JAK inhibitors (filgotinib, tofacitinib, decernotinib, baricitinib, upadacitinib and peficitinib) and 12 interventions (different doses of the six JAK inhibitors), and the control group involved adalimumab (ADA) and placebo. Compared with placebo, all JAK inhibitors showed a significant increase in efficacy measures (ACR20/50/70). Compared with ADA, only tofacitinib, low-dose decernotinib, and high-dose peficitinib showed a significant increase in ACR20/50/70. Decernotinib ranked first in the SUCRA ranking of ACR20/50/70. In terms of safety indicators, only those differences between low-dose filgotinib and high-dose upadacitinib, low-dose tofacitinib and high-dose upadacitinib were statistically significant. Low-dose filgotinib ranked first in the SUCRA ranking with adverse events as safety indicators. Only the efficacy and safety of tofacitinib ranked higher among different SUCRA rankings.
Conclusion
Six JAK inhibitors have better efficacy than placebo. The superior efficacy of decernotinib and safety of low-dose filgotinib can be found in the SUCRA. However, there are no significant differences in safety between the different JAK inhibitors. Head-to-head trials, directly comparing one against each other, are required to provide more certain evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
- Department of Medical Record Management Center, The First Hospital, China Medical University, Shenyang, China.
ORCID-Profile: Lingyu Fu
Förderung
- the Program of the National Natural Science Foundation of China
Zitieren
APA
Qu, B., Zhao, F., Song, Y., Zhao, J., Yao, Y., Chen, Y., Liao, R., & Fu, L. (2024). The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0305621
Vancouver
Qu B, Zhao F, Song Y, Zhao J, Yao Y, Chen Y, et al. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0305621
BibTeX
@article{Qu2024,
author = {Qu, Bingjia and Zhao, Feng and Song, Ying and Zhao, Junyi and Yao, Yuxin and Chen, Yulan and Liao, Ruobing and Fu, Lingyu},
title = {The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305621}
}
EUVIMED